Alessia Petrocchi

IRBM Science Park — Italy

Biochemistry, Genetics and Molecular Biology · Life Sciences

17h-index3.0kcitations49works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(11), HIV/AIDS drug development and treatment(9), Protein Tyrosine Phosphatases(8), Chromatin Remodeling and Cancer(8), Cancer Mechanisms and Therapy(8)

Publications49 total

Novel azabicyclic series of potent SHP2 allosteric inhibitors
Bioorganic & Medicinal Chemistry Letters·2025
Abstract 5614: Advancing treatment for brain tumors and metastases with brain permeable SHP2 inhibitor I-1000233
Cancer Research·2025
A patent review of SHP2 allosteric inhibitors (2018-present)
Expert Opinion on Therapeutic Patents·2024· 7 cited
Abstract 1975: Discovery of I-1000233, a potent, selective and brain permeable SHP2 allosteric inhibitor
Cancer Research·2024
Direct-to-biology platform: From synthesis to biological evaluation of SHP2 allosteric inhibitors
Bioorganic & Medicinal Chemistry Letters·2024· 5 citedOpen Access
Direct-to-Biology Platform: From Synthesis to Biological Evaluation of Shp2 Allosteric Inhibitors
SSRN Electronic Journal·2024Open Access
Discovery of a Novel Series of Potent SHP2 Allosteric Inhibitors
ACS Medicinal Chemistry Letters·2023· 11 citedOpen Access
supplementary Figures S1-S10 from Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer
2023Open Access
Data from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
2023Open Access
Data from Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer
2023Open Access
Supplementary Figures 1 - 8 from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
2023Open Access
Supplementary Figures 1 - 8 from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
2023Open Access
supplementary material and method from Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer
2023Open Access
Supplementary Methods, Figure Legends from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
2023Open Access
Supplementary Methods, Figure Legends from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
2023Open Access
Data from Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer
2023Open Access
Data from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
2023Open Access
supplementary Figures S1-S10 from Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer
2023Open Access
supplementary material and method from Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer
2023Open Access
Discovery of a Novel Series of Imidazopyrazine Derivatives as Potent SHP2 Allosteric Inhibitors
ACS Medicinal Chemistry Letters·2023· 16 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Carlo Toniatti(28), Giulio Draetta(20), Timothy P. Heffernan(16), Parantu K. Shah(15), Elisabetta Leo(14), Joseph R. Marszalek(13), Xi Shi(12), Wylie S. Palmer(12), Philip Jones(11), Vincenzo Summa(11), Yanai Zhan(10), Jannik N. Andersen(10), Philip H. Jones(10), Maria Emilia Di Francesco(9), Michael Rowley(9), Trang N. Tieu(9), Alessandro Carugo(9), Angela K. Deem(8), Ronald A. DePinho(8), Bhavatarini Vangamudi(8)